VANCOUVER, British Columbia, March 23, 2015 /PRNewswire/— InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN;OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced that it has received a notice from Health Canada dated March 12, 2014, approving InMed’s application for an exemption under Section 56 of theControlled  Drugs and Substances Act.

This exemption allows InMed to use a specified quantity of selected Cannabinoid compounds including Delta 9-Tetrahydrocannabinol and Cannabidiol. Importantly this exemption allows InMed to possess the controlled substance and to administer them for Research & Development purposes which include; in vitro studies as well as the use of these compounds in animal models of human diseases.

Craig Schneider, President & CEO states, “Obtaining this exemption is a critical milestone for InMed as we prepare for human clinical studies for our lead programs in Glaucoma (CTI-085) and Arthritis (CTI-091) moving towards the clinical development of their respective proprietary delivery systems”.

The Office of Controlled Substance licensed dealers has also been notified so that it may import the controlled substances on behalf of InMed.

About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing cannabis based therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMeds’ Proprietary Platform Technology, Product pipeline and accelerated development pathway are the fundamental value drivers of the Company.

ON BEHALF OF THE BOARD

This news release may contain forward-looking statements and information based on current expectations.  These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct.  We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/inmed-receives-exemption-status-from-health-canada-300054169.html